The University of Würzburg has a clear focus on life sciences and is unique in its long tradition in performing highly collaborative interdisciplinary cancer research, and its proven ability to successfully define and address topics at the interface of clinical and basic medicine. In particular, biomedical research at the University of Würzburg has repeatedly received outstanding evaluations, e.g. as the "Iead institution in basic biomedicine" and “one of the top universities in medicine” in the national DFG-ranking. The University Hospital Würzburg (1.433 in-patient beds), has a total permanent staff of 5.379, of which 768 are physicians, 105 biologists and 11 pharmacists, involved in both clinical care and academic research. The Würzburg group was the first in Europe to explore T-cell adoptive immunotherapy to treat infections after bone marrow transplantation in leukaemia patients, and pioneered the use of bi-specific antibodies to redirect T cells to treat certain types of leukaemia and lymphoma. The group is recognized internationally as a Centre of Excellence in Stem Cell Transplantation and Cell Therapy, runs one of the largest leukaemia (>100 patients with acute leukaemia per year) and stem cell transplantation programs in Germany (>280 per year) and has a designated Phase I Unit for early clinical studies. The group also runs one of the largest clinical programs in multiple myeloma in Europe, with more than 50 newly diagnosed patients per year and a patient registry of more than 5.000 patients. The research team has specific expertise in T-cell selection, expansion and transfer, gene transfer to redirect T cells (CAR/TCR), dendritic cell vaccination, pre-clinical tumour models as well as in vivo imaging.